Inari Medical, Inc. (NASDAQ:NARI) Stake Lessened by Victory Capital Management Inc.

Victory Capital Management Inc. trimmed its stake in shares of Inari Medical, Inc. (NASDAQ:NARI) by 9.1% during the third quarter, HoldingsChannel reports. The fund owned 9,721 shares of the company’s stock after selling 970 shares during the quarter. Victory Capital Management Inc.’s holdings in Inari Medical were worth $401,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in NARI. GAMMA Investing LLC lifted its position in shares of Inari Medical by 164.7% during the second quarter. GAMMA Investing LLC now owns 704 shares of the company’s stock worth $34,000 after purchasing an additional 438 shares during the last quarter. Nisa Investment Advisors LLC raised its stake in Inari Medical by 83.5% during the second quarter. Nisa Investment Advisors LLC now owns 956 shares of the company’s stock valued at $46,000 after buying an additional 435 shares in the last quarter. Benjamin F. Edwards & Company Inc. lifted its holdings in Inari Medical by 39.4% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 1,847 shares of the company’s stock worth $89,000 after buying an additional 522 shares during the last quarter. Covestor Ltd grew its position in shares of Inari Medical by 63.5% in the 3rd quarter. Covestor Ltd now owns 2,384 shares of the company’s stock worth $99,000 after acquiring an additional 926 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Inari Medical in the 2nd quarter worth approximately $104,000. 90.98% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, CEO Andrew Hykes sold 3,000 shares of the company’s stock in a transaction dated Tuesday, October 29th. The shares were sold at an average price of $50.00, for a total value of $150,000.00. Following the completion of the sale, the chief executive officer now owns 445,310 shares of the company’s stock, valued at $22,265,500. This represents a 0.67 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director William Hoffman sold 60,000 shares of the firm’s stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $51.16, for a total transaction of $3,069,600.00. Following the transaction, the director now directly owns 501,233 shares in the company, valued at approximately $25,643,080.28. The trade was a 10.69 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 186,000 shares of company stock valued at $8,990,990 in the last three months. 10.60% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

NARI has been the subject of a number of research reports. Canaccord Genuity Group lifted their price objective on shares of Inari Medical from $71.00 to $74.00 and gave the stock a “buy” rating in a report on Tuesday, October 29th. Stifel Nicolaus started coverage on shares of Inari Medical in a report on Tuesday, September 17th. They issued a “hold” rating and a $50.00 price target for the company. Needham & Company LLC reaffirmed a “hold” rating on shares of Inari Medical in a research report on Tuesday, October 29th. Leerink Partnrs upgraded Inari Medical to a “hold” rating in a research note on Tuesday, September 3rd. Finally, Piper Sandler upped their target price on Inari Medical from $50.00 to $52.00 and gave the company a “neutral” rating in a report on Tuesday, October 29th. Six analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $58.89.

Inari Medical Trading Up 1.7 %

Shares of NASDAQ:NARI opened at $51.92 on Friday. The firm’s 50 day moving average is $46.14 and its two-hundred day moving average is $47.48. The firm has a market capitalization of $3.04 billion, a P/E ratio of -37.80 and a beta of 0.96. Inari Medical, Inc. has a 52 week low of $36.73 and a 52 week high of $67.13.

Inari Medical Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.